C-24WP

FILE C-24WP·COMPANY·CURATED BY ETERNAL SEARCH

Gameto

cell engineering, iPSC-derived technology, ovarian support cells

replacementreplacingcell therapy

gametogen.com·United States·$44M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-24WP

Projects

Ovary-in-a-dish cell engineering platform

exploratory

platform · medium · Thu Aug 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Create human-like ovarian tissue models to support reproductive-health applications across fertility, ovarian disease, and menopause.

Reprogram donated skin cells into induced pluripotent stem cells and engineer them into ovarian tissue or ovarian support cells, including ovaries of women of different ages and induced disease states.

Described in 2025 as an indefinitely available bank of ovarian tissue and human-like ovaries in a dish used as the basis for Gameto's programs.

Implant for ovarian decline

preclinical

research program · medium · Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop an implant for ovarian decline and methods of manufacturing an implant for ovarian decline.

Implantable or injectable composition for ovarian decline, described in a Gameto-assigned patent.

US patent US11744920B1 granted on 2023-09-05.

Ameno

undisclosed

drug program · high

Delay or reduce the unwanted medical effects of menopause and make the medical burden of menopause optional.

Menopause-related cell therapy based on Gameto's proprietary cell-engineering platform.

Supported by an ARPA-H Sprint for Women's Health Initiative funding award according to the supplied site excerpt.

Deovo

exploratory

platform · high

Test and develop drugs for ovarian disease.

Ovarian disease drug-testing platform using Gameto's cell-engineering technology and ovary-in-a-dish approach.

Listed on Gameto's pipeline as a program for testing and developing drugs for ovarian disease.

Fertilo

undisclosed

other · high

Improve IVF, egg freezing, and other fertility outcomes by maturing eggs outside the body.

Uses engineered ovarian support cells derived from Gameto's cell-engineering/iPSC platform to support ex vivo egg maturation.

FDA-cleared testing of an easier IVF process; reported as coming to market and already associated with 9 births in supplied public-record excerpts.

Reported to have helped with 9 births.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

Ovary-in-a-dish cell engineering platform

exploratory

platform · medium · Thu Aug 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Create human-like ovarian tissue models to support reproductive-health applications across fertility, ovarian disease, and menopause.

Described in 2025 as an indefinitely available bank of ovarian tissue and human-like ovaries in a dish used as the basis for Gameto's programs.

Implant for ovarian decline

preclinical

research program · medium · Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop an implant for ovarian decline and methods of manufacturing an implant for ovarian decline.

Implantable or injectable composition for ovarian decline, described in a Gameto-assigned patent.

US patent US11744920B1 granted on 2023-09-05.

Ameno

undisclosed

drug program · high

Delay or reduce the unwanted medical effects of menopause and make the medical burden of menopause optional.

Menopause-related cell therapy based on Gameto's proprietary cell-engineering platform.

Supported by an ARPA-H Sprint for Women's Health Initiative funding award according to the supplied site excerpt.

Deovo

exploratory

platform · high

Test and develop drugs for ovarian disease.

Ovarian disease drug-testing platform using Gameto's cell-engineering technology and ovary-in-a-dish approach.

Listed on Gameto's pipeline as a program for testing and developing drugs for ovarian disease.

Fertilo

undisclosed

other · high

Improve IVF, egg freezing, and other fertility outcomes by maturing eggs outside the body.

Uses engineered ovarian support cells derived from Gameto's cell-engineering/iPSC platform to support ex vivo egg maturation.

FDA-cleared testing of an easier IVF process; reported as coming to market and already associated with 9 births in supplied public-record excerpts.

Reported to have helped with 9 births.